ReviewAAPS PharmSciTech2026
Recent Advances in Surface-Engineered Polymeric Nanoparticles for Targeted Paclitaxel Delivery in Breast Cancer Therapy.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polymeric Therapeutic Nanosystems Containing Paclitaxel: Novel Strategies, Therapeutic Potential, Challenges, and Translation Problems.Materials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a leading cause of cancer-related mortality worldwide. Paclitaxel (PTX), a first-line chemotherapeutic agent widely used in breast cancer, is widely used due to its potent mechanism of action against rapidly dividing cancer cells. However, its clinical application is significantly hindered by poor solubility, systemic toxicity, and associated adverse effects. Encapsulating PTX in polymeric nanoparticles presents a promising strategy to overcome these limitations by extending drug release, enhancing drug's bioavailability, and enabling active targeting. This review uniquely focuses on recent advances in surface-functionalized polymeric nanoparticles specifically engineered for targeted delivery of PTX in breast cancer therapy and consolidates their translational relevance and next-generation design considerations. Unlike general reviews on polymeric nanocarriers, this article specifically focuses on ligand-functionalized polymeric nanoparticles designed for active targeting of breast cancer cells, integrating biological rationale, receptor specificity, and translational relevance. Surface-engineered polymeric nanoparticles functionalized with ligands such as folic acid, hyaluronic acid, aptamers, and peptides can specifically target overexpressed receptors on cancer cells, including CD44, HER2, and folate receptors. These ligand-receptor interactions facilitate receptor-mediated endocytosis, enhancing intracellular drug delivery while minimizing systemic toxicity. The review highlights key design considerations, including ligand density, nanoparticle architecture, and multifunctionality of next-generation PTX nanocarriers. The development of PTX-loaded polymeric nanoparticles with surface modifications represents a significant advancement in precision drug delivery for breast cancer, addressing key treatment challenges and paving the way for clinical translation.
Indexed as
Identifiers
41963751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.